NZ761478B2 - Antagonist antibodies directed against calcitonin gene-related peptide and methods using same - Google Patents
Antagonist antibodies directed against calcitonin gene-related peptide and methods using sameInfo
- Publication number
- NZ761478B2 NZ761478B2 NZ761478A NZ76147815A NZ761478B2 NZ 761478 B2 NZ761478 B2 NZ 761478B2 NZ 761478 A NZ761478 A NZ 761478A NZ 76147815 A NZ76147815 A NZ 76147815A NZ 761478 B2 NZ761478 B2 NZ 761478B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- monoclonal antibody
- subject
- cdr
- seq
- formulated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
The invention features methods for preventing or treating CGRP associated disorders, in particular migraine headache by administering an anti-CGRP antagonist antibody at a dose of 675mg once every three months.
Claims (21)
1. Use of a monoclonal antibody that inhibits the calcitonin gene-related peptide (CGRP) pathway in the manufacture of a medicament for treating or reducing the incidence of migraine headache in a subject, 5 wherein the monoclonal antibody is formulated to be administered at a dose of about 675 mg once every three months, and wherein the monoclonal antibody comprises a CDR H1 as set forth in SEQ ID NO: 3; a CDR H2 as set forth in SEQ ID NO: 4; a CDR H3 as set forth in SEQ ID NO: 5; a CDR L1 as set forth in SEQ ID NO: 6; a 10 CDR L2 as set forth in SEQ ID NO: 7; and a CDR L3 as set forth in SEQ ID NO: 8.
2. The use of claim 1, wherein the migraine headache is chronic migraine headache.
3. The use of claim 1, wherein the migraine headache is episodic 15 migraine headache.
4. The use of any one of claims 1 to 3, wherein the incidence of migraine headache is reduced for at least seven days after a single administration.
5. The use of any one of claims 1 to 4, wherein monthly headache 20 hours experienced by the subject after said administering is reduced by 40 or more hours from a pre-administration level in the subject.
6. The use of any one of claims 1 to 5, wherein monthly headache days experienced by the subject after said administering is reduced by 3 or more days from a pre-administration level in the subject. 25
7. The use of any one of claims 1 to 6, wherein monthly headache hours experienced by the subject after said administering is reduced by 25% or more relative to a pre-administration level in the subject.
8. The use of any one of claims 1 to 7, wherein the monoclonal antibody is formulated for subcutaneous administration. 161
9. The use of any one of claims 1 to 7, wherein the monoclonal antibody is formulated for intravenous administration.
10. The use of any one of claims 1 to 9, wherein the monoclonal antibody is formulated to be administered by utilizing a pre-filled 5 syringe comprising the amount of the monoclonal antibody.
11. The use of any one of claims 1 to 10, wherein the monoclonal antibody is formulated at a concentration of at least 150 mg/mL.
12. The use of any one of claims 1 to 11, wherein the monoclonal antibody is formulated to be administered in a volume of less than 2 10 mL.
13. The use of any one of claims 1 to 12, wherein the dose of 675 mg of the monoclonal antibody is formulated to be administered as three injections of 225 mg each.
14. The use of claim 13, wherein each 225mg injection is 1.5 mL.
15.15. The use of any one of claims 1 to 14, wherein the medicament further comprises a second agent formulated to be administered simultaneously or sequentially with the monoclonal antibody to the subject or wherein the monoclonal antibody is formulated to be administered simultaneously or sequentially with a second agent to 20 the subject.
16. The use of claim 15, wherein the second agent is selected from the group consisting of: 5-HT1 agonists, triptans, ergot alkaloids, and non-steroidal anti-inflammatory drugs.
17. The use of claim 15 or claim 16, wherein use of the second agent by 25 the subject is decreased by at least 15% after administering the monoclonal antibody.
18. The use of any one of claims 15 to 17, wherein the second agent is a triptan. 162
19. The use of any one of claims 1 to 18, wherein the monoclonal antibody is human or humanized.
20. The use of any one of claims 1 to 19, wherein the monoclonal 5 antibody is formulated to be administered via injections into the abdomen, thigh, or upper arm of the subject’s body.
21. Use of a monoclonal antibody that inhibits the calcitonin gene-related peptide (CGRP) pathway in the manufacture of a medicament for treating or reducing the incidence of migraine headache in a subject, 10 wherein the monoclonal antibody is formulated to be administered at a dose of 675 mg once every three months, wherein the monoclonal antibody comprises (a) an antibody having a CDR H1 as set forth in SEQ ID NO: 3; a CDR H2 as set forth in SEQ ID NO: 4; a CDR H3 as set forth in SEQ ID NO: 5; a CDR L1 as set forth in SEQ ID NO: 15 6; a CDR L2 as set forth in SEQ ID NO: 7; and a CDR L3 as set forth in SEQ ID NO: 8; and wherein the 675 mg dose is formulated to be administered as three consecutive 225 mg subcutaneous injections of 1.5 mL to the abdomen, thigh, or upper arm of the subject’s body
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461968897P | 2014-03-21 | 2014-03-21 | |
| US201462083809P | 2014-11-24 | 2014-11-24 | |
| US201562119778P | 2015-02-23 | 2015-02-23 | |
| NZ724442A NZ724442B2 (en) | 2014-03-21 | 2015-03-20 | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ761478A NZ761478A (en) | 2024-01-26 |
| NZ761478B2 true NZ761478B2 (en) | 2024-04-30 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017510579A5 (en) | ||
| FI3227675T3 (en) | Activin-actrii antagonists and uses for treating myelodysplastic syndrome | |
| JP2012067116A5 (en) | ||
| JP2022531939A5 (en) | ||
| US20250177364A1 (en) | Combination therapies for breast cancer | |
| JP2018531938A5 (en) | ||
| JP2015525798A5 (en) | ||
| FI3356386T3 (en) | Method for treating disorders related to the melanocortin-4 receptor pathway | |
| RU2014101207A (en) | NEW INDICATIONS FOR USE IN TREATMENT BY ANTIBODIES AGAINST IL-1-BETA | |
| CA2939464A1 (en) | Use of anti-ccr5 antibodies in graft versus host disease | |
| RU2015152860A (en) | INTRODUCTION MODE AND COMPOSITIONS FOR TYPE B Adenoviruses | |
| JP2019508433A5 (en) | ||
| FI3464380T3 (en) | Dosing regimen for gp100-specific tcr - anti-cd3 scfv fusion protein | |
| US20200069680A1 (en) | Oxabicycloheptanes for modulation of immune response | |
| JP2016526531A5 (en) | ||
| RU2012108108A (en) | CONCENTRATED POLYPEPTIDE MEDICINAL FORMS WITH REDUCED VISCOSITY | |
| IL292706A (en) | Inhibition of type i interferon in systemic lupus erythematosus | |
| RU2009118962A (en) | APPLICATION OF IL-1 ANTAGONISTS FOR TREATMENT OF GHIT AND PSEUDOGRAPHY | |
| JP2020512978A5 (en) | ||
| WO2009075813A1 (en) | Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4) | |
| CN111836647A (en) | Combination of CD47 blockade therapy and CD38 antibody | |
| RU2020111574A (en) | HIGHLY CONCENTRATED, LOW-VISCOUS PREPARATIONS OF INHIBITING MASP-2 ANTIBODIES, KITS AND METHODS FOR TREATMENT OF SUBJECTS SUFFERING WITH ATYPICAL HEMOLYTIC SYNDROME | |
| Cooper et al. | A pharmacological review of calcitonin gene-related peptide biologics and future use for chronic pain | |
| Alvarez et al. | Gastrin induces leukocyte‐endothelial cell interactions in vivo and contributes to the inflammation caused by Helicobacter pylori | |
| IL273909B1 (en) | Treatment of CD20-positive B-cell lymphoma with obinutuzumab |